BioNTech SE (BNTX) Latest Stock News & Headlines - Yahoo …
Get the latest BioNTech SE (BNTX) stock news and headlines to help you in your trading and investing decisions.
BioNTech To Buy Biotheus In Upfront Payment Of $800 Mln
21 hours ago · Nov. 13, 2024, 08:10 AM. (RTTNews) - BioNTech SE (BNTX) announced Tuesday that it has signed an agreement to acquire Biotheus, a clinical-stage biotechnology company focused on novel antibodies ...
BioNTech Acquires Biotheus to Enhance Cancer Therapies
1 day ago · Nov. 13, 2024, 06:19 AM. BioNTech SE (BNTX) has released an update. BioNTech SE is set to acquire Biotheus in a deal valued at $800 million, aiming to strengthen its oncology strategy by securing ...
BioNTech to Acquire Biotheus for $800 Million to Expand …
15 hours ago · BNTX. BioNTech SE (BNTX, Financials) announced plans to acquire Biotheus, a clinical-stage biotechnology company, for $800 million, securing full global rights to BNT327/PM8002, an investigational ...
BioNTech Boosts Oncology Strategy With $800 Million+ China …
16 hours ago · Price Action: BNTX stock is up 5.87% at $112.57 at the last check on Wednesday. Read Next: Regeneron/Sanofi’s Dupixent Approval Signals Major Treatment Breakthrough For Smokers’ Lung Disease
BioNTech to Acquire Biotheus to Boost Oncology Strategy
23 hours ago · Published. MAINZ, Germany, November 13, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Biotheus (“Biotheus”) today announced the signing of a definitive agreement for ...
BioNTech SE (BNTX) Stock Price, News, Quote & History - Yahoo …
Find the latest BioNTech SE (BNTX) stock quote, history, news and other vital information to help you with your stock trading and investing.
BNTX Stock Price | BioNTech SE ADR Stock Quote (U.S.: Nasdaq ...
2 days ago · BNTX | A complete BNTX overview by MarketWatch. View the latest market news and prices, and trading information.
Pfizer and BioNTech Announce Positive Topline Data for mRNA …
Oct 26, 2023 · NEW YORK & MAINZ, GERMANY-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 …
BioNTech Earns Upgrade From Goldman Sachs As Investment
4 days ago · Goldman Sachs has upgraded BioNTech SE BNTX, citing the company’s BNT327, an immuno-oncology asset in clinical development across multiple solid tumors.. Data from Summit Therapeutics Inc. SMMT ...